United Therapeutics (NASDAQ:UTHR) Price Target Raised to $432.00 at Jefferies Financial Group

United Therapeutics (NASDAQ:UTHR) had its price target lifted by stock analysts at Jefferies Financial Group from $315.00 to $432.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Jefferies Financial Group’s price objective points to a potential upside of 20.71% from the company’s previous close.

Several other equities research analysts have also commented on the company. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. UBS Group increased their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, TD Cowen raised their target price on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $357.17.

United Therapeutics Trading Up 0.6 %

NASDAQ UTHR opened at $357.87 on Monday. The company has a fifty day moving average of $340.35 and a 200 day moving average of $293.69. The company has a market capitalization of $15.87 billion, a PE ratio of 16.92, a P/E/G ratio of 1.25 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $366.08.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same period last year, the firm earned $5.24 EPS. Research analysts forecast that United Therapeutics will post 24.86 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, COO Michael Benkowitz sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $833,350.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $316.62, for a total transaction of $1,139,832.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $41,160.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 114,852 shares of company stock worth $38,079,259. Insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its position in United Therapeutics by 176.2% during the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after buying an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after acquiring an additional 4,100 shares during the last quarter. Comerica Bank grew its holdings in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after purchasing an additional 9,244 shares during the period. QRG Capital Management Inc. increased its position in United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Finally, Tri Locum Partners LP acquired a new stake in United Therapeutics during the second quarter worth about $15,959,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.